Search

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the clinical efficacy and safety of eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria, and to evaluate which patients might benefit most from its use. © 2013 The Cochrane Collaboration.

Aim To describe a case of severe infusion-related reaction to liposomal amphotericin B (LAB). Clinical details A severely immunocompromised 58-year-old male with acute myeloid leukaemia experienced 2 infusion-related adverse events when treated with LAB for a localised Fusarium solani fungal infection of the right forefoot. The initial adverse reaction to LAB was not serious. However, the second adverse reaction following a re-challenge was serious. The patient had a poor prognosis because of the likelihood of further chemotherapy-induced neutropenia and a potentially untreated disseminated fungal infection in light of planned chemotherapy. Outcomes LAB was successfully substituted with conventional amphotericin B to treat Fusarium solani infection. No adverse events were observed with conventional amphotericin B. Conclusion The patient is suspected to have had a reaction to the lipid carrier of LAB.